We build trust in the safety of vaccines through rigorous science.
Case Definitions
This Levels of Diagnostic Certainty (LOC) chart for acute intraocular inflammation (aIOI) is part of the aIOI case definition. This provides a standardized[...]
This Levels of Diagnostic Certainty (LOC) chart for acute Multi-Organ Dysfunction (aMOD) is part of the aMOD case definition. This provides a standardized[...]
This report introduces a Brighton Collaboration (BC) case definition for autoimmune hepatitis (AIH), which has been classified as a priority adverse event of[...]
This is a revision of the online November 2021 Brighton thrombosis with thrombocytopenia syndrome (TTS) case definition and a new Brighton Collaboration case[...]
This deliverable collates into a single document the SPEAC Spontaneous Abortion and Ectopic Pregnancy resources, including the ICD9/10-CM, MedDRA and SNOMED codes, background[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This document includes a Brighton Collaboration case definition of the term “Sensorineural Hearing Loss” (SNHL) as well as guidelines for data collection, analysis,[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Preterm Birth and Assessment of Gestational Age. This and other companion guides have been created as[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This is a Brighton Collaboration case definition of the term “Vaccine-associated Enhanced Disease” (VAED) to be utilized in the evaluation of adverse events[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Thrombosis and Thromboembolism. This and other companion guides have been created as part of the CEPI-funded SPEAC project.[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This is a revision of the Brighton Collaboration Case Definition of the term “Anaphylaxis” to be utilized in the evaluation of adverse events[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This is a Brighton Collaboration Case Definition of the term “Myocarditis” and “Pericarditis” to be utilized in the evaluation of adverse events following[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Generalized Convulsion. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Anaphylaxis. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They contain[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Facial Nerve Palsy. This and other companion guides have been created as part of the CEPI-funded SPEAC project.[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Acute Disseminated Encephalomyelitis (ADEM). This and other companion guides have been created as part of the CEPI-funded SPEAC[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Acute Encephalitis. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Thrombocytopenia. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They contain[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Aseptic Meningitis. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Guillain Barré and Miller Fisher Syndromes. This and other companion guides have been created as part[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This is a The Brighton Collaboration Case Definition of the term “Acute Respiratory Distress Syndrome (ARDS)” to be utilized in the evaluation of[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
Vaccine Safety Templates
Brighton Collaboration Releases New Template for Evaluating VSV-Based Lassa Fever Vaccines The Brighton Collaboration is proud to announce the publication of a new[...]
This manuscript uses the BRAVATO template to report the key considerations for a benefit-risk assessment of the coronavirus disease 2019 (COVID-19) mRNA-based vaccine[...]
This paper uses a BRAVATO protein template to review the features of Novavax’s recombinant adjuvanted spike protein vaccine to prevent disease caused by[...]
Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has[...]
Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology[...]
Replication-incompetent adenoviral vectors have been under investigation as a platform to carry a variety of transgenes, and express them as a basis for vaccine development.[...]
The Modified Vaccinia Ankara (MVA) vector system is being explored as a platform for development of multiple vaccines. This paper reviews the molecular and biological[...]
This paper uses a BRAVATO protein template to review the features of Medigen’s recombinant SARS-CoV-2 spike protein in prefusion stabilized form used to[...]
The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) was formed to evaluate the safety and other key features of new platform[...]
This paper uses the BRAVATO inactivated virus vaccine template to review the features of an inactivated whole chikungunya virus (CHIKV) vaccine that has been evaluated in several preclinical[...]
This paper uses a BRAVATO nucleic acid template to review the features of Moderna’s rapid-response proprietary vaccine platform based on an mRNA delivery[...]
Auro Vaccines LLC has developed a protein vaccine to prevent disease from Nipah and Hendra virus infection that employs a recombinant soluble Hendra glycoprotein (HeV-sG) adjuvanted with aluminum[...]
Several inactivated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration (BC) Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO), as[...]
Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared[...]
Nucleic acid (DNA and RNA) vaccines are among the most advanced vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working[...]
This tool was aimed at identifying potential major hurdles or gaps that would need to be addressed during the development of vectored vaccines.[...]
In this paper, we use a standardized template describing key characteristics of the novel rVSV vaccine vectors, in comparison to wild type VSV. The template[...]
In this paper, we use a standardized template describing the key characteristics of the novel flavivirus vaccine vectors, in comparison to the parental[...]
News
A recent World Health Organization (WHO) publication available through WHO IRIS highlights the importance of standardized approaches to vaccine safety assessment and monitoring[...]
Dear Brighton Community, SPEAC led a Working Group to develop a new Brighton format case definition for “acute multi-organ dysfunction (aMOD)”. The working group[...]
As a program of The Task Force for Global Health, the Brighton Collaboration joins colleagues across the organization and partners worldwide in mourning[...]
Brighton Collaboration News Quarterly Updates From Our Vaccine Safety Community December 2025 Letter from the Science Board - Dr. Robert Chen As we[...]
Dear Brighton Collaboration members:SPEAC is developing a new Brighton format case definition for “Acute Intraocular Inflammation”. This is an AESI that was included[...]
Brighton Collaboration Releases New Template for Evaluating VSV-Based Lassa Fever Vaccines The Brighton Collaboration is proud to announce the publication of a new[...]
This April, global leaders in immunization, public health, and biotechnology convened in Washington, D.C. for the 2025 World Vaccine Congress (WVC)—one of the[...]
Much has been learned about the need for vaccine safety surveillance through COVAX and other recent collaborative efforts. Here, we highlight three recent[...]
The proposed IDT Modified Vaccinia virus Ankara viral vector vaccine manuscript is ready for peer review. The Brighton Collaboration BRAVATO (Benefit-Risk Assessment of[...]
The proposed Clover COVID-19 recombinant protein vaccine manuscript is ready for peer review. The Brighton Collaboration BRAVATO (Benefit-Risk Assessment of VAccines by TechnolOgy)[...]
The World Health Organization (WHO) has reported a ten-fold increase in dengue cases over the past twenty years. Today, nearly 4 billion people[...]
[caption id="attachment_7339" align="alignright" width="300"] Dr. Eileen Farnon, Research Director at Brighton Collaboration The Task Force for Global Health welcomes Dr. Eileen Farnon as[...]
The Vaccine Safety Working Group (VSWG) of COVAX was formed in November 2020 with representatives and consultants representing multiple stakeholders, including Brighton Collaboration,[...]
Vaccine safety data can help build public confidence in vaccines by communicating that the benefits outweigh the risks of immunization. Through the COVID-19 Safety[...]
Global Vaccine Data Network utilises vast data sets to detect potential vaccine safety signals 19 February 2024—The Global Vaccine Data Network (GVDN) assessed[...]
The proposed mRNA BioNTech/Comirnaty manuscript is ready for peer review. The Brighton Collaboration BRAVATO (Benefit-Risk Assessment of VAccines by TechnolOgy) Working Group encourages the Brighton[...]
The multimillion-dollar global initiative will study causes and risk factors, to ensure safer vaccines are ready for the next potential pandemic. EDMONTON —[...]
This editorial by Dr. Robert T. Chen first appeared in the October 2023 issue of Safety by Numbers. It is reposted here with permission from[...]
Dear Brighton Collaboration members: Please find below a draft Brighton Collaboration case definition for both TTS (thrombosis and thrombocytopenia syndrome) and VITT (vaccine-induced[...]
This editorial was previously published in Vaccine Safety Quarterly. Karina Top, MD, MS Karina Top, MD, MS | Principal Investigator,[...]
